Lennox-Gastaut Syndrome (LGS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Lennox-Gastaut syndrome (LGS) is a rare and severe form of childhood epilepsy, falling into the category of severe infantile epileptic syndromes, which includes epileptic neonatal encephalopathy with suppression-burst, West syndrome and severe myoclonic epilepsy of infancy. Typically, LGS manifests with seizures starting in early childhood, typically between ages 3 and 5. It is characterized by significant physical risks for affected children and teenagers, including frequent falls, injuries, and cognitive impairment, severely impacting their quality of life. While LGS may affect children with infantile spasms or underlying brain issues, it can also have an unknown cause (idiopathic). Almost always, antecedent conditions linked to LGS involve the cerebral cortex, with phenomena of LGS stemming from the cerebral cortex and corpus callosum. LGS is most commonly associated with damage to both frontal lobes. However, any brain damage can potentially lead to LGS, and the lack of specificity complicates understanding its neurophysiological mechanisms. Individuals with LGS, including children, adolescents, and adults, experience various types of seizures that vary from person to person. These include:
1. Body stiffening, upward eye gaze, dilated pupils, and altered breathing patterns characterize tonic seizures.
2. Atypical absences, which involve staring spells.
3. Atonic seizures result in a brief loss of muscle tone and potential abrupt falls.
4. Myoclonic seizures cause sudden muscle jerks.
5. Generalized tonic-clonic seizures are marked by muscle stiffness and rhythmic jerking.
In addition to medications approved for general seizure treatment, there are specific drugs approved for managing seizures in individuals with LGS, such as clobazam, rufinamide, topiramate, lamotrigine, felbamate, cannabidiol, fenfluramine, and clonazepam.
• The incidence of Lennox-Gastaut syndrome is extremely low, accounting for approximately 1% of childhood epilepsies in children under 10 years old. The majority of LGS cases, around 68%, occur in children under 18, with the remaining 38% affecting adults. Notably, remission rates are particularly low for LGS, with roughly 50-60% of children who initially experience infantile spasms going on to develop other types of seizures.

Thelansis’s “Lennox-Gastaut Syndrome (LGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lennox-Gastaut Syndrome (LGS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Lennox-Gastaut Syndrome (LGS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Lennox-Gastaut Syndrome (LGS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Lennox-Gastaut Syndrome (LGS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Lennox-Gastaut Syndrome (LGS), Lennox-Gastaut Syndrome (LGS) market outlook, Lennox-Gastaut Syndrome (LGS) competitive landscape, Lennox-Gastaut Syndrome (LGS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)